Daniel Petrylak

21PUBLICATIONS
195CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jan 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.

Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente

|Jul 25, 2025
Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin-driven Tumor Progression and Immune Escape in Prostate Cancer.

Perumalraja Kirthika, Vijayakumar Jawalagatti, Peiyao Li

|Mar 05, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara

|Oct 15, 2024
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Erika Hamilton, Matthew D Galsky, Sebastian Ochsenreither

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

|Aug 01, 2024
Sacituzumab Govitecan Demonstrates Efficacy across Tumor Trop-2 Expression Levels in Patients with Advanced Urothelial Cancer.

Yohann Loriot, Arjun V Balar, Daniel P Petrylak

Pageof 4

Frequent Collaborators

6 joint publications

Cora N Sternberg

4 joint publications

Chethan Ramamurthy

4 joint publications

Rana R McKay

4 joint publications

Scott T Tagawa